Fundraising Fox
Neurelis
Encinitas, US · Delaware corporation · 4 known investors
Find your way into Neurelis
Sign up to see every warm intro you have to Neurelis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurelis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy. It also maintains a proprietary drug delivery and stabilization technology portfolio applicable to proteins, peptides, and small and large molecules.
Founders & leadership
CC
Craig ChamblissCEO and Co-founderFounder of Neurelis, a biopharmaceutical company developing treatments for neurological conditions including epilepsy using proprietary drug delivery technology. Brings experience in corporate development, commercial operations, regulatory affairs, and fundraising.
Board
DF
David F. HaleBoard director
CG
Cam GarnerBoard director
YZ
Yong ZhangBoard director
KL
Investors · 4
HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
HBM Partnerslisted by HBM PartnersZug · $5M – $50M
How we know: HBM Partners's portfolio page · Not right? Tell us
LYZZ Capitallisted by LYZZ CapitalShanghai
How we know: funding news · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$219.1M disclosed across 6 rounds · 2015–2021
▶$114.8MraisedMar 2021 · 9 investors · BiotechnologyRule 506(b)
▶$114.8MraisedMar 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LiDirector
- Huaizheng PengDirector
- Craig C. ChamblissExecutive Officer, Director
- Stephen CarttDirector
- Priyanka BelawatDirector
- David F. HaleDirector
- George StuartExecutive Officer
- Offering amount
- $120M
- Amount sold
- $114.8M
- Sales commissions
- $2.4M
- Placement agents
- Aquilo Partners, L.P.
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.1MraisedOct 2020 · 26 investors · BiotechnologyRule 506(b)
▶$42.1MraisedOct 2020 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Craig C. ChamblissExecutive Officer, Director
- Huaizheng PengDirector
- Kevin LiDirector
- David F. HaleDirector
- George StuartExecutive Officer
- Stephen CarttDirector
- Priyanka BelawatDirector
- Offering amount
- $42.1M
- Amount sold
- $42.1M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.5MraisedNov 2018 · 15 investors · BiotechnologyRule 506(b)
▶$40.5MraisedNov 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. HaleDirector
- Craig C. ChamblissExecutive Officer, Director
- Priyanka BelawatDirector
- Huaizheng PengDirector
- George StuartExecutive Officer
- Kevin LiDirector
- Offering amount
- $40.5M
- Amount sold
- $40.5M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedAug 2018 · 11 investors · BiotechnologyRule 506(b)
▶$5.2MraisedAug 2018 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LiDirector
- George StuartExecutive Officer
- Yong ZhangDirector
- David F. HaleDirector
- Cam L. GarnerDirector
- Craig C. ChamblissExecutive Officer, Director
- Priyanka BelawatDirector
- Offering amount
- $15M
- Amount sold
- $5.2M
- Minimum investment
- $50K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedDec 2017 · 2 investors · BiotechnologyRule 506(b)
▶$15MraisedDec 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yong ZhangDirector
- Priyanka BelawatDirector
- Cam GarnerDirector
- George StuartExecutive Officer
- Craig C. ChamblissExecutive Officer, Director
- David F. HaleDirector
- Kevin LiDirector
- Offering amount
- $20M
- Amount sold
- $15M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJul 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJul 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. HaleDirector
- Cam GarnerDirector
- Craig C. ChamblissExecutive Officer, Director
- Yong ZhangDirector
- Kevin LiDirector
- Offering amount
- $10M
- Amount sold
- $1.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neurelis do?
- Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy. It also maintains a proprietary drug delivery and stabilization technology portfolio applicable to proteins, peptides, and small and large molecules.
- Who founded Neurelis?
- Neurelis was founded by Craig Chambliss.
- Who are Neurelis's investors?
- Neurelis's investors include HBM Healthcare Investments, HBM Partners, LYZZ Capital, OrbiMed.
- How much funding has Neurelis raised?
- Neurelis has disclosed $219.1M raised across 6 rounds.
- Where is Neurelis headquartered?
- Neurelis is headquartered in Encinitas, US.